Orlistat

BreastfeedingPediatric
  • TRADE NAMES: Alli (GSK); Xenical (Roche)
  • INDICATIONS: Obesity, weight reduction
  • CLASS: Lipase inhibitor
  • HALF-LIFE: 1–2 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Acarbose, Amiodarone, Antiepileptics, Coumarins, Cyclosporine, Ergocalciferol, Ethosuximide, Lacosamide, Levothyroxine, Oxcarbazepine, Paricalcitol, Phytonadione, Tiagabine, Vigabatrin, Vitamin A, Vitamin E, Warfarin

PREGNANCY CATEGORY: B

Contra-indicated in organ transplant recipients. Orlistat interferes with the medicines used to prevent transplant rejection.

Our database has 57 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
GENITOURINARY
RENAL
HEMATOLOGIC
OTIC
OTHER


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of orlistat in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 02/12/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric